Doxazosin Mesylate Extended-Release Tablets do not generally shrink the prostate.
Doxazosin Mesylate Extended-Release Tablets do not achieve the effect of shrinking the prostate, its indications for the symptomatic treatment of benign prostatic hyperplasia, as well as the treatment of hypertension. Doxazosin Mesylate Extended-Release Tablets can counteract phenylephrine prostate contraction and reduce peripheral vascular resistance to lower blood pressure. Doxazosin Mesylate Extended-Release Tablets also relieves the symptoms of straining to urinate and dribbling after urination.
Doxazosin Mesylate Extended-Release Tablets are contraindicated in those who are allergic to doxazosin mesylate and quinazoline, those who have had a recent myocardial infarction, and women during pregnancy. Adverse reactions such as respiratory tract infections, urinary tract infections, leukopenia, thrombocytopenia and other adverse reactions may occur after taking Doxazosin Mesylate Extended-Release Tablets.
If you need to use Doxazosin Mesylate Extended-Release Tablets, you should do so under the supervision of a doctor, do not self-medicate.